Differences in expression of predictive biomarkers between primary and metastatic NSCLC

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Zoran Gatalica, MD, DSc, from Caris Life Sciences, Phoenix, AZ, discusses a study evaluating the differences in expression of multiple biomarkers of targeted biological therapies, immune checkpoint inhibitors and chemotherapeutic agents between primary and metastatic tumors in patients with non-small cell lung cancer (NSCLC).
Share this video